Recent clinical studies in patients with bipolar disorder have suggested that, as for other anticonvulsant drugs commonly used in the treatment of bipolar patients including valproate and carbamazepine, phenytoin may have mood-stabilizing effects in addition to its well-known anticonvulsant properties.
In a study published in the March 2010 issue of Experimental Biology and Medicine Veronica Mariotti and colleagues utilized DNA microarrays to investigate the molecular underpinnings of the potential mood-stabilizing action of phenytoin by looking at its effect on gene expression in the rat brain.
As compared with untreated animals, rats treated for a month with phenytoin had 508 differentially expressed genes in the hippocampus and 62 in the frontal cortex, including genes involved in GABAergic and glutamatergic neurotransmission, neuroprotection and other genes thought to be crucial for mood regulation. Furthermore, some of these same genes have been shown to be modulated by classical mood-stabilizer agents, like lithium and valproate.
Thus, the findings of this study indicate that chronic phenytoin administration modulates the expression of genes involved in mood regulation and genes that are targets of established mood stabilizers. Dr Mariotti noted that "The results of this study provide preliminary insights into possible molecular mechanisms of action of phenytoin as a potential mood stabilizer and, more in general, the pathophysiology of bipolar disorders".
The study is the product of a fruitful collaboration between the Molecular Biology Laboratory of Dr. Silvia Pellegrini at the Department of Experimental Pathology, University of Pisa Medical School, Pisa, Italy and the Laboratory of Professors Galila Agam and R.H. Belmaker at the Psychiatry Research Unit at the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, said "Mariotti and colleagues have provided very interesting results on the changes in gene expression in rats treated with phenytoin. There findings shed significant light on the mood altering effects of this antiepileptic drug".
Experimental Biology and Medicine is a journal dedicated to the publication of multidisciplinary and interdisciplinary research in the biomedical sciences. The journal was first established in 1903.
Experimental Biology and Medicine is the journal of the Society of Experimental Biology and Medicine. To learn about the benefits of society membership visit www.sebm.org. If you are interested in publishing in the journal please visit www.ebmonline.org.
Not of Divided Mind
19.01.2017 | Hertie-Institut für klinische Hirnforschung (HIH)
CRISPR meets single-cell sequencing in new screening method
19.01.2017 | CeMM Forschungszentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
19.01.2017 | Earth Sciences
19.01.2017 | Life Sciences
19.01.2017 | Physics and Astronomy